Related Experiment Videos

TRAF1: lord without a RING

Juan M Zapata1, John C Reed

  • 1Burnham Institute, La Jolla, CA 92037, USA. jzapata@burnham.org

Insights

Tumor necrosis factor (TNF) receptor-associated factors (TRAFs) are adaptor proteins. TRAF1 acts as a negative regulator of TNF signaling, as shown by hyper-responsive T cells and increased skin necrosis in TRAF1-deficient mice.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • Tumor necrosis factor (TNF) receptor-associated factors (TRAFs) are adaptor proteins crucial for cytokine signaling.
  • Six TRAF family members (TRAF1-6) exist in mammals, mediating signals from TNF-family receptors (TNFRs).
  • TRAF1 is unique, lacking a RING finger domain and exhibiting restricted expression in immune cells and epithelia.

Purpose of the Study:

  • To review current knowledge on TRAF1, emphasizing findings from TRAF1-deficient mice.
  • To explore the role of TRAF1 as a negative regulator of TNF-family receptor signaling.
  • To discuss the potential of TRAFs as drug discovery targets.

Main Methods:

  • Analysis of data from TRAF1-deficient (TRAF1(-/-)) mice.
  • In vitro assessment of T cell receptor (TCR)-dependent T cell proliferation.
  • In vivo evaluation of sensitivity to TNF-alpha-induced skin necrosis.

Main Results:

  • TRAF1-deficient T cells exhibit hyper-responsiveness to TNF-alpha.
  • Increased T cell proliferation rates were observed in TRAF1-deficient T cells in vitro.
  • TRAF1-deficient mice showed heightened sensitivity to TNF-alpha-induced skin necrosis in vivo.

Conclusions:

  • TRAF1 functions as a negative regulator of signaling pathways initiated by certain TNF-family receptors.
  • TRAF1 deficiency leads to exaggerated responses to TNF-alpha.
  • TRAFs present both opportunities and challenges as targets for therapeutic drug development.

Related Concept Videos